{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T10:56:23Z","timestamp":1777114583208,"version":"3.51.4"},"reference-count":58,"publisher":"American Society of Hematology","issue":"20","license":[{"start":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T00:00:00Z","timestamp":1722556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>For several decades, induction therapy with nucleoside analogs, in particular cytarabine (Ara-C) and, to a lesser extent, fludarabine, has been the standard of care for patients diagnosed with acute myeloid leukemia (AML). However, the antitumor efficacy of nucleoside analogs is often limited by intrinsic and acquired drug resistance, thereby leading to poor therapeutic response and suboptimal clinical outcomes. In this study, we used genome-wide CRISPR-based pharmacogenomic screening to map the genetic factors that modulate the response to nucleoside analogs in AML and identified the E3 ubiquitin ligase, Herc1, as a key modulator of Ara-C response in mouse AML models driven by the KMT2A\/MLLT3 fusion or by the constitutive coexpression of\u00a0Hoxa9\u00a0and\u00a0Meis1, both in\u00a0vitro and in\u00a0vivo. Loss of HERC1 enhanced nucleoside analog\u2013induced cell death in both murine and human AML cell lines by compromising cell cycle progression. In-depth proteomic analysis and subsequent validation identified deoxycytidine kinase as a novel target of Herc1 in both mouse AML models. We observed that HERC1 is overexpressed in AML when compared with other cancer types and that higher HERC1 expression was associated with shorter overall survival in patients with AML in the The Cancer Gene Atlas program (TCGA) and BEAT-AML cohorts. Collectively, this study highlights the importance of HERC1 in the response of AML cells to nucleoside analogs, thereby establishing this E3 ubiquitin ligase as a novel predictive biomarker and potential therapeutic target for the treatment of AML.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011540","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T17:53:21Z","timestamp":1722621201000},"page":"5315-5329","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["The E3 ubiquitin ligase Herc1 modulates the response to nucleoside analogs in acute myeloid leukemia"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-3811","authenticated-orcid":false,"given":"Maja","family":"Jankovic","sequence":"first","affiliation":[{"name":"1Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, Canada"},{"name":"2Division of Experimental Medicine, Department of Medicine, McGill University, Montr\u00e9al, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William W. L.","family":"Poon","sequence":"additional","affiliation":[{"name":"1Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, Canada"},{"name":"2Division of Experimental Medicine, Department of Medicine, McGill University, Montr\u00e9al, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7256-2649","authenticated-orcid":false,"given":"Cristobal","family":"Gonzales-Losada","sequence":"additional","affiliation":[{"name":"1Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, Canada"},{"name":"2Division of Experimental Medicine, Department of Medicine, McGill University, Montr\u00e9al, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela Galicia","family":"Vazquez","sequence":"additional","affiliation":[{"name":"1Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahram","family":"Sharif-Askari","sequence":"additional","affiliation":[{"name":"1Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[{"name":"3State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constance","family":"Craplet-Desombre","sequence":"additional","affiliation":[{"name":"1Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandru","family":"Ilie","sequence":"additional","affiliation":[{"name":"1Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0039-8800","authenticated-orcid":false,"given":"Jiantao","family":"Shi","sequence":"additional","affiliation":[{"name":"3State Key Laboratory of Molecular Biology, Shanghai Institute of Biochemistry and Cell Biology, University of Chinese Academy of Sciences, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7035-5382","authenticated-orcid":false,"given":"Yongjie","family":"Wang","sequence":"additional","affiliation":[{"name":"4Proteomics and Cancer Cell Signaling Group, German Cancer Research Center, Heidelberg, Germany"},{"name":"5Department of Pediatric Oncology, Hematology, and Immunology, Hopp Children\u2019s Cancer Center, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-1117","authenticated-orcid":false,"given":"Ashok Kumar","family":"Jayavelu","sequence":"additional","affiliation":[{"name":"4Proteomics and Cancer Cell Signaling Group, German Cancer Research Center, Heidelberg, Germany"},{"name":"5Department of Pediatric Oncology, Hematology, and Immunology, Hopp Children\u2019s Cancer Center, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Orthwein","sequence":"additional","affiliation":[{"name":"1Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, Canada"},{"name":"2Division of Experimental Medicine, Department of Medicine, McGill University, Montr\u00e9al, Canada"},{"name":"6Gerald Bronfman Department of Oncology, McGill University, Montr\u00e9al, Canada"},{"name":"7Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5324-2167","authenticated-orcid":false,"given":"Fran\u00e7ois \u00c9mile","family":"Mercier","sequence":"additional","affiliation":[{"name":"1Lady Davis Institute for Medical Research, Jewish General Hospital, Montr\u00e9al, Canada"},{"name":"2Division of Experimental Medicine, Department of Medicine, McGill University, Montr\u00e9al, Canada"},{"name":"8Division of Hematology, Department of Medicine, McGill University, Montr\u00e9al, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"issue":"12","key":"2024102112501951100_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"issue":"22","key":"2024102112501951100_bib2","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2024102112501951100_bib3","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients: the ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am J Hematol"},{"issue":"2","key":"2024102112501951100_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41408-019-0170-3","article-title":"Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?","volume":"9","author":"Yilmaz","year":"2019","journal-title":"Blood Cancer J"},{"key":"2024102112501951100_bib5","volume-title":"SEER","year":"2021"},{"key":"2024102112501951100_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fmolb.2017.00078","article-title":"Inhibiting DNA polymerases as a therapeutic intervention against cancer","volume":"4","author":"Berdis","year":"2017","journal-title":"Front Mol Biosci"},{"issue":"50","key":"2024102112501951100_bib7","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1038\/onc.2008.316","article-title":"Nucleoside analogs: molecular mechanisms signaling cell death","volume":"27","author":"Ewald","year":"2008","journal-title":"Oncogene"},{"issue":"7","key":"2024102112501951100_bib8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3390\/cancers10070240","article-title":"Nucleobase and nucleoside analogues: resistance and re-sensitisation at the level of pharmacokinetics, pharmacodynamics and metabolism","volume":"10","author":"Tsesmetzis","year":"2018","journal-title":"Cancers"},{"key":"2024102112501951100_bib9","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1038\/srep06048","article-title":"Using RNA-seq and targeted nucleases to identify mechanisms of drug resistance in acute myeloid leukemia","volume":"4","author":"Rathe","year":"2014","journal-title":"Sci Rep"},{"issue":"1","key":"2024102112501951100_bib10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41375-022-01755-2","article-title":"Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia","volume":"37","author":"Ling","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"2024102112501951100_bib11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nm.4255","article-title":"SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia","volume":"23","author":"Schneider","year":"2017","journal-title":"Nat Med"},{"issue":"2","key":"2024102112501951100_bib12","first-page":"324","article-title":"The downregulation of both giant HERCs, HERC1 and HERC2, is an unambiguous feature of chronic myeloid leukemia, and HERC1 levels are associated with leukemic cell differentiation","volume":"11","author":"Ali","year":"2022","journal-title":"J\u00a0Clin Med"},{"issue":"12","key":"2024102112501951100_bib13","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1002\/ijc.29350","article-title":"Resistance to UV-induced apoptosis by beta-HPV5 E6 involves targeting of activated BAK for proteolysis by recruitment of the HERC1 ubiquitin ligase","volume":"136","author":"Holloway","year":"2015","journal-title":"Int J Cancer"},{"issue":"17","key":"2024102112501951100_bib14","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1182\/bloodadvances.2022007250","article-title":"In\u00a0vivo genome-wide CRISPR screening in murine acute myeloid leukemia uncovers microenvironmental dependencies","volume":"6","author":"Mercier","year":"2022","journal-title":"Blood Adv"},{"issue":"12","key":"2024102112501951100_bib15","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","article-title":"MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens","volume":"15","author":"Li","year":"2014","journal-title":"Genome Biol"},{"issue":"1","key":"2024102112501951100_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13073-019-0665-3","article-title":"Identifying chemogenetic interactions from CRISPR screens with drugZ","volume":"11","author":"Colic","year":"2019","journal-title":"Genome Med"},{"issue":"database issue","key":"2024102112501951100_bib17","doi-asserted-by":"crossref","first-page":"D447","DOI":"10.1093\/nar\/gku1003","article-title":"STRING v10: protein-protein interaction networks, integrated over the tree of life","volume":"43","author":"Szklarczyk","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"2024102112501951100_bib18","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.celrep.2016.09.079","article-title":"A\u00a0CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia","volume":"17","author":"Tzelepis","year":"2016","journal-title":"Cell Rep"},{"issue":"32","key":"2024102112501951100_bib19","doi-asserted-by":"crossref","first-page":"eadf4082","DOI":"10.1126\/sciadv.adf4082","article-title":"FIRRM cooperates with FIGNL1 to promote RAD51 disassembly during DNA repair","volume":"9","author":"Pinedo-Carpio","year":"2023","journal-title":"Sci Adv"},{"issue":"15","key":"2024102112501951100_bib20","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"issue":"1","key":"2024102112501951100_bib21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2024102112501951100_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinf"},{"issue":"12","key":"2024102112501951100_bib23","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"14","key":"2024102112501951100_bib24","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.1021\/ac502040v","article-title":"MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes","volume":"86","author":"McAlister","year":"2014","journal-title":"Anal Chem"},{"issue":"7","key":"2024102112501951100_bib25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1101\/gad.1771409","article-title":"Mouse models of human AML accurately predict chemotherapy response","volume":"23","author":"Zuber","year":"2009","journal-title":"Genes Dev"},{"issue":"7104","key":"2024102112501951100_bib26","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature04980","article-title":"Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9","volume":"442","author":"Krivtsov","year":"2006","journal-title":"Nature"},{"issue":"13","key":"2024102112501951100_bib27","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1093\/emboj\/17.13.3714","article-title":"Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b","volume":"17","author":"Kroon","year":"1998","journal-title":"EMBO J"},{"issue":"6166","key":"2024102112501951100_bib28","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1247005","article-title":"GeCKO v2. pooled libraries","volume":"343","author":"Shalem","year":"2014","journal-title":"Science"},{"issue":"6","key":"2024102112501951100_bib29","doi-asserted-by":"crossref","first-page":"e1309","DOI":"10.1002\/ctm2.1309","article-title":"Identification of IKZF1 genetic mutations as new molecular subtypes in acute myeloid leukaemia","volume":"13","author":"Wang","year":"2023","journal-title":"Clin Transl Med"},{"issue":"4","key":"2024102112501951100_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-05-714493","article-title":"The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia","volume":"129","author":"Li","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2024102112501951100_bib31","doi-asserted-by":"crossref","first-page":"e0259197","DOI":"10.1371\/journal.pone.0259197","article-title":"A\u00a0B-cell developmental gene regulatory network is activated in infant AML","volume":"16","author":"Bolouri","year":"2021","journal-title":"PLoS One"},{"issue":"14","key":"2024102112501951100_bib32","doi-asserted-by":"crossref","first-page":"e3682","DOI":"10.21769\/BioProtoc.3682","article-title":"A\u00a0CRISPR competition assay to identify cancer genetic dependencies","volume":"10","author":"Girish","year":"2020","journal-title":"Bio Protoc"},{"issue":"8","key":"2024102112501951100_bib33","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/10428190802210700","article-title":"Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia","volume":"49","author":"Rao","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2024102112501951100_bib34","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bjc.6603559","article-title":"Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells","volume":"96","author":"Nakano","year":"2007","journal-title":"Br J Cancer"},{"issue":"7391","key":"2024102112501951100_bib35","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"key":"2024102112501951100_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0076-6879(08)01606-6","article-title":"DNA damage response and apoptosis","volume":"446","author":"Plesca","year":"2008","journal-title":"Methods Enzymol"},{"issue":"1","key":"2024102112501951100_bib37","doi-asserted-by":"crossref","first-page":"11344","DOI":"10.1038\/s41598-022-15520-z","article-title":"Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis","volume":"12","author":"Tomic","year":"2022","journal-title":"Sci Rep"},{"key":"2024102112501951100_bib38","author":"Garcia-Gonzalo","year":"2003"},{"issue":"59","key":"2024102112501951100_bib39","doi-asserted-by":"crossref","first-page":"31531","DOI":"10.18632\/oncotarget.25847","article-title":"The E3 ubiquitin ligase HERC1 controls the ERK signaling pathway targeting C-RAF for degradation","volume":"9","author":"Schneider","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"2024102112501951100_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41419-023-05549-x","article-title":"HERC1 deficiency causes osteopenia through transcriptional program dysregulation during bone remodeling","volume":"14","author":"Pedrazza","year":"2023","journal-title":"Cell Death Dis"},{"issue":"6558","key":"2024102112501951100_bib41","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1126\/science.abc6500","article-title":"Identification of a quality-control factor that monitors failures during proteasome assembly","volume":"373","author":"Zavodszky","year":"2021","journal-title":"Science"},{"issue":"13","key":"2024102112501951100_bib42","doi-asserted-by":"crossref","first-page":"8313","DOI":"10.1074\/jbc.C500451200","article-title":"TSC1 stabilizes TSC2 by inhibiting the interaction between TSC2 and the HERC1 ubiquitin ligase","volume":"281","author":"Chong-Kopera","year":"2006","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"2024102112501951100_bib43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccell.2022.02.006","article-title":"The proteogenomic subtypes of acute myeloid leukemia","volume":"40","author":"Jayavelu","year":"2022","journal-title":"Cancer Cell"},{"issue":"7664","key":"2024102112501951100_bib44","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nature23270","article-title":"In\u00a0vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target","volume":"547","author":"Manguso","year":"2017","journal-title":"Nature"},{"issue":"5","key":"2024102112501951100_bib45","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.cmet.2019.01.011","article-title":"Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of drug sensitivity","volume":"29","author":"Lin","year":"2019","journal-title":"Cell Metab"},{"issue":"7","key":"2024102112501951100_bib46","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"issue":"2","key":"2024102112501951100_bib47","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1158\/2159-8290.CD-20-1851","article-title":"An in\u00a0vivo CRISPR screening platform for prioritizing therapeutic targets in AML","volume":"12","author":"Lin","year":"2022","journal-title":"Cancer Discov"},{"issue":"3","key":"2024102112501951100_bib48","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1158\/2643-3230.BCD-22-0086","article-title":"In\u00a0vivo screening unveils pervasive RNA-binding protein dependencies in leukemic stem cells and identifies ELAVL1 as a therapeutic target","volume":"4","author":"Vujovic","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2024102112501951100_bib49","doi-asserted-by":"crossref","first-page":"36199","DOI":"10.1038\/srep36199","article-title":"Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML","volume":"6","author":"Kurata","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"2024102112501951100_bib50","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40364-021-00320-w","article-title":"Deubiquitinases in hematological malignancies","volume":"9","author":"Lei","year":"2021","journal-title":"Biomark Res"},{"issue":"16","key":"2024102112501951100_bib51","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1182\/blood.2019004108","article-title":"CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy","volume":"137","author":"Soares","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2024102112501951100_bib52","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41419-022-05023-0","article-title":"Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis"},{"issue":"2","key":"2024102112501951100_bib53","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41375-020-0878-x","article-title":"Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy","volume":"35","author":"Cartel","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"2024102112501951100_bib54","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000513696","article-title":"Deoxycytidine kinase (DCK) mutations in human acute myeloid leukemia resistant to cytarabine","volume":"144","author":"Wu","year":"2021","journal-title":"Acta Haematol"},{"issue":"4","key":"2024102112501951100_bib55","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood.V96.4.1517","article-title":"High incidence of alternatively spliced forms of deoxycytidine kinase in patients with resistant acute myeloid leukemia","volume":"96","author":"Veuger","year":"2000","journal-title":"Blood"},{"issue":"3","key":"2024102112501951100_bib56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1034\/j.1600-0609.2002.02785.x","article-title":"Deoxycytidine kinase expression and activity in patients with resistant versus sensitive acute myeloid leukemia","volume":"69","author":"Veuger","year":"2002","journal-title":"Eur J Haematol"},{"issue":"4","key":"2024102112501951100_bib57","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1182\/blood.V99.4.1373","article-title":"Functional role of alternatively spliced deoxycytidine kinase in sensitivity to cytarabine of acute myeloid leukemic cells","volume":"99","author":"Veuger","year":"2002","journal-title":"Blood"},{"key":"2024102112501951100_bib58","doi-asserted-by":"crossref","first-page":"32.1.1","DOI":"10.1002\/cpmb.52","article-title":"Pooled lentiviral-delivery genetic screens","volume":"121","author":"Piccioni","year":"2018","journal-title":"Current Protocols in Molecular Biology"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/20\/5315\/2247464\/blooda_adv-2023-011540r1-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/20\/5315\/2247464\/blooda_adv-2023-011540r1-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T12:50:45Z","timestamp":1729515045000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/20\/5315\/517264\/The-E3-ubiquitin-ligase-Herc1-modulates-the"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":58,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,10,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011540","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]}}}